<DOC>
	<DOCNO>NCT01586325</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ( drug absorb distribute body ) , intrinsic antiviral activity JNJ-47910382 5 consecutive day administration chronic , hepatitis C virus ( HCV ) -genotype-1-infected patient different dos dose regimen .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics , Antiviral Activity JNJ-47910382 Different Doses Dose Regimens Asian Genotype-1 , Chronic , HCV-Infected Patients</brief_title>
	<detailed_description>This double-blind ( neither physician patient know name assign drug ) , randomize ( patient assign chance treatment group ) placebo-controlled study . A placebo inactive substance compare drug test whether drug real effect . The study population consist Asian treatment-naive genotype-1 , chronic HCV-infected patient . The trial involve screen period maximum 6 week baseline , 9-day treatment period ( 5 day actual medication intake ) 4-week follow-up period . Patients divide 3 panel 8 patient ( Panel 1 ) 5 patient ( Panels 2 3 ) . Treatment initiated panel patient sequentially . In panel , patient receive JNJ-47910382 placebo 5 consecutive day . JNJ-47910382 , placebo , administer daily . Treatments take mouth standardized meal dose regimen . Patient safety monitor .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Documented chronic HCV infection ( diagnosis hepatitis C &gt; = 6 month screen period ) HCV geno subtype 1a 1b ( Panel 1 ) 1b ( Panels 2 3 ) Patient never receive pegylated interferon , ribavirin , approve investigational antiviral treatment chronic HCV infection Patient HCV ribonucleic acid ( RNA ) level &gt; 100,000 IU/mL screening ( assessed standard quantitative vitro nucleic acid amplification assay ) A Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 32.0 kg/m2 , extremes include A body weight 50 kg Normal 12lead electrocardiogram ( ECG ) screen Evidence document liver cirrhosis Evidence decompensated liver disease Evidence cause significant liver disease addition hepatitis C History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , Investigator 's opinion would compromise patient 's safety and/or compliance study procedures A positive urine drug ( exclusion methadone equivalent ) test study screen Patient protocoldefined laboratory abnormality screen Patient coinfected HIV1 HIV2 , hepatitis A B virus infection , active tuberculosis study screen Patient infected/coinfected nongenotype 1 HCV study screen Patient cardiac disease screening , active clinically significant disease ( eg , cardiac dysfunction , cardio ( myo ) pathy , cardiac insufficiency ) , medical history physical examination finding screen , Investigator 's opinion , would compromise outcome trial Patient uncontrolled/unstable disease diabetes , epilepsy , manifest psychiatric disease , thyroid disease disorder Patient nonstable methadone ( equivalent drug ) use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Chronic hepatitis C infection</keyword>
	<keyword>Asian genotype 1 chronic hepatitis C infection</keyword>
	<keyword>JNJ-47910382</keyword>
	<keyword>Non-structural protein 5A ( NS5A ) inhibitor</keyword>
</DOC>